MITCHELL FREDERICK to Molecular Targeted Therapy
This is a "connection" page, showing publications MITCHELL FREDERICK has written about Molecular Targeted Therapy.
Connection Strength
0.292
-
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck. 2014 Nov; 36(11):1547-54.
Score: 0.087
-
Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013 Sep; 12(9):1860-73.
Score: 0.083
-
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck. 2011 Mar; 33(3):349-58.
Score: 0.070
-
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
Score: 0.026
-
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601.
Score: 0.026